Neutral
Pfizer's stock remains steady at $27.96 as FDA approves updated COVID-19 vaccine.
Pfizer's stock price has remained steady at $27.96 following the FDA's approval of its updated COVID-19 vaccine for the 2026-27 season. Analysts maintain a 'Hold' rating with a price target of $28.28, indicating cautious sentiment despite the vaccine approval.
Key points
- FDA approves Pfizer's updated COVID-19 vaccine for 2026-27 season.
- Analysts maintain 'Hold' rating with price target of $28.28.
- Pfizer's stock price remains steady at $27.96.
Sources
AI-generated from public news sources. Not financial advice.
